.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Cantor Fitzgerald
Boehringer Ingelheim
Chinese Patent Office
Federal Trade Commission
US Department of Justice
Chubb
Covington
Express Scripts
Citi

Generated: November 18, 2017

DrugPatentWatch Database Preview

FLOVENT DISKUS 50 Drug Profile

« Back to Dashboard

What is the patent landscape for Flovent Diskus 50, and what generic Flovent Diskus 50 alternatives are available?

Flovent Diskus 50 is a drug marketed by Glaxo Grp Ltd and is included in one NDA. There is one patent protecting this drug.

This drug has seventy-eight patent family members in forty-one countries and four supplementary protection certificates in three countries.

The generic ingredient in FLOVENT DISKUS 50 is fluticasone propionate. There are twenty-five drug master file entries for this compound. Eighty suppliers are listed for this compound. Additional details are available on the fluticasone propionate profile page.

Pharmacology for FLOVENT DISKUS 50

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxo Grp Ltd
FLOVENT DISKUS 50
fluticasone propionate
POWDER;INHALATION020833-001Sep 29, 2000RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: FLOVENT DISKUS 50

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,536,427 Inhalation device► Subscribe
2,006,107,948► Subscribe
5,860,419 Inhalation device► Subscribe
7,389,775Inhalation device► Subscribe
6,378,519 Inhalation device► Subscribe
5,590,645 Inhalation device► Subscribe
6,792,945 Inhalation device► Subscribe
2,007,107,724► Subscribe
6,032,666 Inhalation device► Subscribe
7,225,808Inhalation device► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: FLOVENT DISKUS 50

Country Document Number Estimated Expiration
China1107687► Subscribe
Norway910836► Subscribe
Czech Republic285501► Subscribe
China1066036► Subscribe
Denmark37991► Subscribe
African Regional IP Organization (ARIPO)9100321► Subscribe
Australia645056► Subscribe
African Intellectual Property Organization (OAPI)9393► Subscribe
Austria401007► Subscribe
France2659558► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: FLOVENT DISKUS 50

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB08/026United Kingdom► SubscribePRODUCT NAME: FLUTICASONE FUROATE AND SOLVATES THEREOF; REGISTERED: UK EU/1/07/434/001 20080111; UK EU/1/07/434/002 20080111; UK EU/1/07/434/003 20080111
269Luxembourg► SubscribePRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE
C0067France► SubscribePRODUCT NAME: AZELASTINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE; NAT. REGISTRATION NO/DATE: NL41755 20130925; FIRST REGISTRATION: SK - 24/0055/13-S 20130215
C0014France► SubscribePRODUCT NAME: FLUTICASONE FUROATE; REGISTRATION NO/DATE: EU/1/07/434/001 20080111
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Federal Trade Commission
Colorcon
AstraZeneca
QuintilesIMS
Moodys
Express Scripts
Citi
Julphar
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot